Sort
10,766 grants matching “checkpoint inhibitor”
Mechanism and inhibition of SREBP-dependent cholesterol/lipid metabolism
$581,500Gerhard Wagner · Harvard Medical School · R01 · FY2013 · HL
A Phase 1 Trial of MLN0128 (sapanisertib) and CB-839 HCl (telaglenastat) in Advanced NSCLC Patients
$581,481Paul K Paik · Sloan-Kettering Inst Can Research · R01 · FY2023 · CA
Development of a novel therapy targeting the tumor microenvironment in inflammatory breast cancer
$581,465Naoto T Ueno · University Of Hawaii At Manoa · R01 · FY2023 · CA
Molecular Basis for Myelodysplasia Induced by U2AF1 Mutations
$581,381Golam Mohi · University Of Virginia · R01 · FY2025 · HL
Molecular Basis for Myelodysplasia Induced by U2AF1 Mutations
$581,381Golam Mohi · University Of Virginia · R01 · FY2023 · HL
Credentialing Mouse Models for Immune System Therapy Research
$581,304Charles M Perou · Univ Of North Carolina Chapel Hill · R01 · FY2016 · CA
Credentialing Mouse Models for Immune System Therapy Research
$581,304Charles M Perou · Univ Of North Carolina Chapel Hill · R01 · FY2017 · CA
Overcoming Immunotherapy Resistance Through Opioid Antagonism in Head and Neck Cancer
$581,147Nicole N Scheff · University Of Pittsburgh At Pittsburgh · R01 · FY2024 · DE
Genetically-engineered Bacteria Overcome Therapy Resistance
$581,087Ralph R Weichselbaum · University Of Chicago · R01 · FY2024 · CA
Molecular Digital CytoImaging for Leukemia Drug Screening
$581,084Tothu Q Vu · Oregon Health & Science University · R01 · FY2021 · CA
Systems analysis of cell-cell communication networks and immune activity in the melanoma tumor microenvironment
$581,057Kathryn Miller-Jensen · Yale University · U01 · FY2020 · CA
Targeting the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer with a Neoadjuvant Platform Clinical Trial
$581,039Lei Zheng · Johns Hopkins University · R01 · FY2021 · CA
Regulation and Function of Stromal Macropinocytosis in Pancreatic Ductal Adenocarcinoma
$580,946Cosimo Commisso · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2021 · CA
Novel CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy
$580,914Farrokh Dehdashti · Washington University · R01 · FY2020 · CA
Development of an autologous humanized model of melanoma exploring human thymic education capacity
$580,793Antonio Jimeno · University Of Colorado Denver · R01 · FY2019 · CA
Development of an autologous humanized model of melanoma exploring human thymic education capacity
$580,793Antonio Jimeno · University Of Colorado Denver · R01 · FY2017 · CA
(8) Mechanisms of autoimmune endocrine diseases in patients receiving checkpoint inhibitors
$580,767Kevan C Herold · Yale University · R01 · FY2018 · CA
Discovery of the next-generation RET-targeted drugs based on nicotinamide scaffold
$580,663Jie Wu · University Of Oklahoma Hlth Sciences Ctr · R01 · FY2025 · CA
Understanding IDH mutant gliomas
$580,621Jing Wu · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Cell type-directed Tim-3 targeting in melanoma
$580,109Steven Russell Barthel · Brigham And Women'S Hospital · R01 · FY2025 · CA
Tumor Endothelial Cell Regulation of Pro-Metastatic Fibrin Matrices
$580,098Chad V Pecot · Univ Of North Carolina Chapel Hill · R01 · FY2025 · CA
Innate lymphoid cell regulation of the host-microbiota interactions in cancer
$580,093Gregory F Sonnenberg · Weill Medical Coll Of Cornell Univ · R01 · FY2022 · CA
(8) Mechanisms of autoimmune endocrine diseases in patients receiving checkpoint inhibitors
$580,072Kevan C Herold · Yale University · R01 · FY2021 · CA
Genotypes and Phenotypes of Apoptosis and Risk of Head and Neck Cancer
$579,943Qingyi Wei · University Of Tx Md Anderson Can Ctr · R01 · FY2012 · CA
Epigenetic and immunologic aspects of neuroendocrine cancers
$579,811Nitin Roper · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA